Sfoglia per Autore
Autoimmunity profile in interferon beta-1a treated Multiple Sclerosis patients. The AUPRIN Study: comparison of 2 different dosages of subcutaneous interferon beta-1a
2004-01-01 E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; G. AIMO; T. M. PACIELLO; T. TASSINARI; L. MOTTI; A. REGGIO; L. DURELLI; THE AUPRIN STUDY GROUP
Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a.
2004-01-01 E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; T. TASSINARI; L. MOTTI; M. PACIELLO; A. REGGIO; G. AIMO; L. DURELLI; ON BEHALF OF THE AUPRIN STUDY GROUP
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study.
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI
The OPTimization of interferon for MS (OPTIMS) study. A multicenter trial comparing two different doses (250 and 375 mcg) of IFN beta-1b
2004-01-01 L. Durelli; E. Verdun; P. Barbero; M. Bergui; A. Pipieri; A. Ricci; M. Clerico; A. Cucci; L. Giordano; G. B. Bradac
Mxa protein and interleukin-10 (il-10) leukocyte production and anti-ifn neutralizing antibody(nab) occurrence in relapsing remitting multiple sclerosis (rrms) patients treated with different doses of interferon (ifn) beta- 1b
2004-01-01 M. CLERICO; A. RICCI; E. VERDUN; A. CUCCI; A. PIPIERI; P. BARBERO; E. VERSINO; L. GIORDANO; L. DURELLI; AND THE OPTIMIZING OF IFN BETA B DOSE MS OPTIMS STUDY GROUP
Interferon-beta-1b in multiple sclerosis: comparing two different doses (the OPTIMS Study)
2004-01-01 L. Durelli; E. Verdun; P. Barbero; A. Pipieri; A. Ricci; M. Clerico; M. A. Gucci; L. Giordano; M. Bergui; E. Versino
High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose
2004-01-01 P. Barbera; A. Pipieri; E. Verdun; M. Clerico; A. Ricci; M. A. Cucci; L. Giordano; E. Cartechini; G. Giuliani; E. Montanari; M. Bergui; L. Durelli
Mxa protein, interleukin-10 and neutralising antibody in MS patients treated with different doses of Interferon-Beta-1b
2004-01-01 A. RICCI; M. CLERICO; M.A. CUCCI; P. BARBERO; E. VERDUN; A. PIPIERI; L. GIORDANO; L. DURELLI; ON BEHALF OF THE OPTIMS STUDY GROUP
Interleukin-17 t lymphocyte production correlates with disease activity in Multiple Sclerosis
2004-01-01 G. CONTESSA; L. CONTI; M. CLERICO; C. RIVOIRO; A. TAVELLA; C. FERRERO; E. PICCO; A. GHEZZI; M. ZAFFARONI; F. NOVELLI; L. DURELLI
IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study).
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; M. BERGUI; E. VERSINO; L. GIORDANO; M. ZAFFARONI; E. MONTANARI; G. GIULIANI; L. DURELLI; AND THE OPTIMS STUDY GROUP
High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study
2004-01-01 BARBERO P; VERDUN E; BERGUI M; PIPIERI A; CLERICO M; CUCCI A; RICCI A; BERGAMASCO B; DURELLI L
Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial
2004-01-01 P. BARBERO; M. BERGUI; A. RICCI; E. VERSINO; A. PIPIERI; E. VERDUN; M. CLERICO; L. GIORDANO; A. CUCCI; L. DURELLI; INCOMIN STUDY GROUP
Looking for treatment response indicator. real- time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors in Multiple Sclerosis patients treated with ifn beta 1b: correlation with mri response
2005-01-01 A. CUCCI; A. RICCI; M. CLERICO; E. VERDUN; L. GIORDANO; P. BARBERO; A. PIPIERI; B. FERRERO; E. FESTA; L. DURELLI
Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to Multiple Sclerosis: a cochrane review.
2005-01-01 M. CLERICO; J. PALACE; M. TINTORE SUBIRANA; G. RICE; F. FAGGIANO; L. DURELLI
Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a
2005-01-01 E. VERDUN; L. GIORDANO; M.A. CUCCI; A. RICCI; P. BARBERO; A. PIPIERI; M. CLERICO; G. AIMO; L. DURELLI; THE AUPRIN STUDY GROUP
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation
2005-01-01 A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP
To evaluate anti-interferon (ifn) neutralizing antibody (nab) in relapsing remitting (rr) ms patients treated over the long term with an ifn beta-1b dose higher than that currently approved.
2005-01-01 A. RICCI; P. BARBERO; A PIPIERI; B. FERRERO; M. CUCCI; M. CLERICO; G. CONTESSA; L. GIORDANO; L. DURELLI; AND THE OPTIMS STUDY GROUP
Treatment for delaying conversion of the first demyelinating event to Multiple Sclerosis: a cochrane review on use of recombinant interferon beta or glatiramer acetate
2005-01-01 M. CLERICO; F. FAGGIANO; J. PALACE; G. RICE; M. TINTOR; L. DURELLI
The optims trial: the first prospective long term predictivity analysis trial of a treatment response marker to immunomodulatory drug in ms.
2005-01-01 L. DURELLI; P. BARBERO; M. CLERICO; A. RICCI; B. FERRERO; G. CONTESSA; E. VERSINO; G. GIULIANI; E. MONTANARI; AND THE OPTIMS STUDY GROUP; ITALY
Mxa protein: correlation with magnetic resonance imaging response in relapsing-remitting multiple sclerosis patients treated with two different ifn beta doses
2005-01-01 A. RICCI; P. BARBERO; A. PIPIERI; E. VERDUN; M. CLERICO; A. CUCCI; L. GIORDANO; B. FERRERO; E. FESTA; L. DURELLI; THE OPTIMS STUDY GROUP
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile